Indivisible Partners Purchases New Shares in Merck & Co., Inc. $MRK

Indivisible Partners purchased a new stake in Merck & Co., Inc. (NYSE:MRK) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 12,823 shares of the company’s stock, valued at approximately $1,350,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in Merck & Co., Inc. by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company’s stock valued at $26,770,014,000 after acquiring an additional 2,185,853 shares during the period. DLD Asset Management LP boosted its stake in Merck & Co., Inc. by 30.1% during the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock worth $3,986,675,000 after purchasing an additional 11,000,000 shares during the last quarter. Legal & General Group Plc boosted its stake in Merck & Co., Inc. by 5.9% during the 3rd quarter. Legal & General Group Plc now owns 20,659,157 shares of the company’s stock worth $1,733,923,000 after purchasing an additional 1,156,112 shares during the last quarter. Invesco Ltd. boosted its stake in Merck & Co., Inc. by 16.6% during the 3rd quarter. Invesco Ltd. now owns 19,844,936 shares of the company’s stock worth $1,665,585,000 after purchasing an additional 2,821,766 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its stake in Merck & Co., Inc. by 20.7% during the 3rd quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company’s stock worth $1,336,877,000 after purchasing an additional 2,735,459 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck completed the acquisition of Terns Pharmaceuticals, adding clinical-stage oncology assets to its pipeline—a near-term catalyst for growth and synergy expectations. Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
• Positive Sentiment: Analysts and commentators point to continued KEYTRUDA-driven revenue and a strong pipeline; Merck delivered its fourth straight beat, supporting the view the stock may be undervalued on a longer-term basis. Merck Stock Looks Undervalued as KEYTRUDA Growth and Pipeline Offset Near-Term Headwinds
• Positive Sentiment: High-profile media support: Jim Cramer highlighted Merck’s solid quarter and said the stock is “starting to come back,” which can boost retail demand and sentiment. Jim Cramer on Merck & Co.: “The Stock’s Starting to Come Back”
• Neutral Sentiment: Institutional commentary: recent investor letters and analyst write-ups (e.g., Baron Capital coverage) review Merck as a core healthcare holding—useful background but not an immediate catalyst. What Makes Merck & Co. (MRK) an Investment Bet?
• Neutral Sentiment: Sector news: Pfizer beat Q1 estimates but faces a looming patent cliff; competitive results and sector rotation can influence pharma multiples and investor attention, creating mixed pressure across large peers including Merck. Pfizer Beats Sales Estimates As $17 Billion Patent Cliff Looms
• Negative Sentiment: Technical/short-term risk: chart analysts warn a double-top breakdown and moving-average pressures that could produce a deeper correction, which may cap near-term upside despite fundamental positives. Merck (MRK) Price Forecast: Double Top Signals Deeper Correction Risk

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 37,685 shares of the business’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $120.92, for a total value of $4,556,870.20. Following the transaction, the executive vice president directly owned 160,174 shares in the company, valued at $19,368,240.08. The trade was a 19.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP David Michael Williams sold 5,000 shares of the business’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $121.91, for a total transaction of $609,550.00. Following the completion of the transaction, the executive vice president owned 30,838 shares in the company, valued at $3,759,460.58. The trade was a 13.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 209,258 shares of company stock worth $25,101,593 over the last ninety days. 0.17% of the stock is currently owned by insiders.

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $113.21 on Wednesday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30. The firm has a market capitalization of $279.62 billion, a price-to-earnings ratio of 31.89, a PEG ratio of 2.24 and a beta of 0.18. The company’s 50-day moving average is $117.51 and its two-hundred day moving average is $107.91. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.19. The company had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 26.84%. Merck & Co., Inc.’s revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the business posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Analysts forecast that Merck & Co., Inc. will post 5.15 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on MRK. Deutsche Bank Aktiengesellschaft raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 target price on the stock in a research note on Friday, February 13th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $142.00 target price on shares of Merck & Co., Inc. in a research note on Monday, March 30th. Wolfe Research raised shares of Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 target price on the stock in a research note on Thursday, January 8th. Guggenheim lifted their target price on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Finally, Zacks Research raised shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $128.18.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.